Cullinan Therapeutics, Inc.
CGEM
$8.74
-$0.33-3.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.05% | -9.28% | 8.07% | -0.28% | -302.52% |
| Total Depreciation and Amortization | -2.55% | -1.29% | 4.79% | 40.27% | 106.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.61% | 17.17% | -21.63% | -19.62% | 107.78% |
| Change in Net Operating Assets | 150.14% | -14.75% | 78.06% | 90.96% | -179.58% |
| Cash from Operations | -23.61% | -8.21% | 10.15% | 21.40% | 21.98% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 96.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -434.45% | -478.50% | -132.95% | -159.57% | 175.82% |
| Cash from Investing | -434.94% | -480.70% | -127.69% | -175.99% | -85.37% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 573.69% | 595.26% | 592.79% | 565.50% | 802.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12,455.56% | -- | 86.64% | 88.61% | 100.11% |
| Cash from Financing | 561.98% | 553.21% | 3,389.05% | 2,860.93% | 244.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.07% | 73.27% | 120.94% | 87.34% | -204.11% |